Question 1

Is it safe to take PT-141 two days in a row?

Accepted Answer

We cannot tell you that any schedule carries no risk, but this is one of the few questions here with a regulator's answer behind it. A 2020 review states that prescribing guidelines recommend no more than 1 dose in 24 hours and no more than 8 doses per month. That ceiling was not picked at random. The 2022 safety review of the development programme reports that focal hyperpigmentation was rare when bremelanotide was dosed in accordance with label recommendations, but it occurred in more than one-third of subjects following up to 16 consecutive daily dosings. Focal hyperpigmentation means darkened patches of skin. So two days in a row sits inside the labelled limit, while sixteen days produced a visible effect in a third of the people who did it. Both numbers belong to the approved injection, given under trial conditions, rather than to an unlabelled vial on the same schedule.

Question 2

What are the common side effects of PT-141?

Accepted Answer

These were counted rather than estimated, which makes them unusual on this site, and the numbers come from the two Phase 3 trials, pooled into one safety population of 1,247 women. In that pooled group, nausea reached 40.0% against 1.3% on placebo, flushing reached 20.3% against 1.3%, headache 11.3% against 1.9%, and injection site reactions 5.4% against 0.5%. A 2020 review of the same trials gives nausea (39.9%), facial flushing (20.4%), and headache (11%). Two points carry the weight here. The placebo column is what turns a symptom into an effect, because 40% against 1.3% is not chance, and four in ten is not a rare event, so nausea was the usual experience rather than the unlucky one. The trial report adds that most treatment-emergent adverse events were related to tolerability and the majority were mild or moderate in intensity.

Question 3

What are the risks of using PT-141?

Accepted Answer

The serious end of the record is short, and belongs beside the common end rather than apart from it. Across the Phase 3 programme there were no deaths; a few subjects experienced serious AEs, and the 2022 review concludes that the AEs associated with bremelanotide are mostly mild to moderate. Two cautions sit underneath that. The first is cardiovascular: although not deemed clinically important, bremelanotide should be used with caution in patients at risk of cardiovascular disease, and blood pressure should be well controlled during treatment. The second is the skin, covered in its own section below. Read the shape of this. A compound with 18 months of supervised exposure and a labelled caution sits in a different position from one with neither. The caution also names a group the trials screened out rather than studied, so it rests on prudence rather than on an observed outcome.

Question 4

Is it safe to take PT-141 every day?

Accepted Answer

Daily use sits outside the approved schedule, and the one run that went there found something you can see. In the development programme, darkened patches of skin showed up in more than one-third of subjects following up to 16 consecutive daily dosings. At the labelled frequency they were rare. The approved pattern is not a daily one in the first place, which is why daily dosing had to be examined separately. A 2020 review calls bremelanotide a shot under the skin, taken as needed about 45 minutes before sex, with the monthly ceiling set out above. That review also says use should stop after 8 weeks without benefit, which sets a stopping rule rather than a schedule. Sixteen days is still only sixteen days, and no study among the research behind this page has published what daily use does to skin or blood pressure over months, so a daily schedule is unstudied rather than cleared.

Question 5

Does PT-141 raise blood pressure?

Accepted Answer

Yes, measurably, and the size of the effect is the useful part. The 2022 safety review reports that small and transient but statistically significant blood pressure increases were observed during ambulatory blood pressure monitoring, which means a monitor worn through a full day rather than a single reading in a clinic. Small and transient are the authors' words, and significant means the rise was real rather than noise. The review's own conclusion is that although not deemed clinically important, bremelanotide should be used with caution in patients at risk of cardiovascular disease, and blood pressure should be well controlled during treatment. Hold those two sentences together. A rise that does not matter in screened women with a mean age of 39 is not automatically a rise that does not matter in somebody older, or already on blood pressure medicine. The trials did not enrol that second person.

Question 6

Does PT-141 darken your skin?

Accepted Answer

It can, and how often depends entirely on the schedule. Taken as the label directs, bremelanotide rarely caused focal hyperpigmentation, but after up to 16 consecutive daily doses it appeared in more than one-third of subjects. This is the least surprising finding in the record, because of what the compound is. A 2006 review of this receptor family notes that related analogues have been patented and tested clinically for studies on tanning of the skin (MTI) and for diagnosis and treatment of male erectile dysfunction (MTII). Pigment and sexual response run through the same receptor system, so one arrives with the other. The practical reading is about frequency: at the labelled frequency the effect was rare, and at sixteen straight days it reached a third of people. No study among the research behind this page has published what happens between those points, or a reversal rate, so whether the patches faded is unrecorded rather than resolved.

Question 7

What does PT-141 interact with?

Accepted Answer

An approval calls for interaction testing, so for once that testing exists and has been published. The 2022 review reports that most drug-drug interactions were not clinically significant. That is a real finding and a narrow one. There was one exception, and it runs the other way from the usual worry. Bremelanotide lowered plasma concentrations of indomethacin and naltrexone, rather than those two raising its own level. Both are medicines people take for other reasons: indomethacin is a painkiller for swelling, and naltrexone is used in addiction care. For a reader who takes either, the question is whether their own medicine still works as well. Alcohol was checked on its own, and a 2020 review records limited drug-drug interactions, including no clinically significant interactions with ethanol, which is alcohol. Everything outside that short list is untested rather than cleared. The testing used the approved shot, at the labelled schedule, in the trial group.

Question 8

What are the side effects of PT-141 for women?

Accepted Answer

Every number on this page came from women, so this is the whole safety record rather than a subgroup of it, and the two Phase 3 trials gave bremelanotide to premenopausal women for 24 weeks. A longer look came after that. Of the 856 eligible patients who completed the core phase, 684 elected to participate in the open-label extension, and 272 completed it. Over that year the most common treatment-emergent adverse events considered related to study drug were nausea (40.4%), flushing (20.6%), and headache (12.0%). The only severe one shared by more than one woman, in both trials, was nausea. Notice that the rates barely moved between six months and eighteen, and that what changed was who was left: a fifth of the women who started the extension finished it, which says something the side-effect table does not.

Question 9

What are the side effects of PT-141 for men?

Accepted Answer

No trial among the research behind this page reports an adverse-event table for men, and the reason is a programme that stopped. According to a 2004 industry note, Palatin had finished a phase IIb trial in patients with ED by September 2003. A 2006 review adds that PT-141 has initial phase I/II trials and is scheduled to enter pivotal stage III clinical trials leading to commercialization. Those Phase 3 trials, when they came, enrolled women, and no adverse-event table in men has been published in the two decades since that programme stopped. A 2025 review of peptides for erectile dysfunction still lists PT-141 as a candidate and still concludes that large-scale clinical trials are needed to establish safety profiles, optimal dosing regimens. Two decades on, that sentence has not changed. Men are not a group in whom the compound was found harmless, but a group in whom it was never measured, and those are different questions.

Question 10

Is PT-141 nasal spray safe?

Accepted Answer

No approved nasal product exists, and no trial among the research behind this page reports the safety of one. The nasal route is where this compound started, rather than where it ended up. A 2004 industry note describes Palatin developing PT-141 as a nasal spray for erectile dysfunction and female sexual dysfunction. What reached approval fifteen years later was something else, since a 2019 review calls bremelanotide a self-administered, on-demand subcutaneous therapy, which means a shot under the skin. Every number on this page belongs to that shot, and none of it carries over to a spray, because a new route changes how much gets into the blood. A 2025 experiment shows the size of that gap. A patch held against the cheek lining of beagle dogs reached a relative bioavailability of 26% for bremelanotide, which is a quarter of what the injection delivers.

Question 11

How much human safety data actually exists?

Accepted Answer

More than for anything else on this site, and it is still a finite amount. The clinical development program comprised 3500 subjects in 43 completed studies, and in the phase 3 studies, subjects took bremelanotide for up to 18 months, which is the longest documented exposure anywhere. The core of that is two matched trials. Of the 1,267 women randomized, 1,247 were in the safety population, and patients were randomized 1:1 to 24 weeks of treatment or placebo. A later analysis covered 1202 patients included in the integrated and subgroup analyses. One older paper has to be set aside. A 2008 article on the safety of bremelanotide in women was later retracted at the request of the Editor-in-Chief. The journal stated that we can no longer verify the results or methods as presented. Anything resting on that paper is resting on a withdrawn result rather than on evidence.

Question 12

Why did people stop taking it in the trials?

Accepted Answer

Because of how it felt, and the numbers are specific. Nausea was the most common reason for bremelanotide discontinuation, in a programme where four in ten reported it. A 2021 re-analysis of the same trial data puts a figure on the gap. It reports that adverse event-induced study discontinuation was substantially higher on bremelanotide: OR = 11.98, 95% CI = 3.74-38.37, NNH: 6. An odds ratio near twelve means people on bremelanotide left because of side effects at roughly twelve times the rate of people on placebo. The choice to continue says the same thing from another angle. In the double-blind portion of the integrated phase 3 studies, 70% of the bremelanotide group proceeded to the open-label phase of the studies versus 87% of those on placebo. The re-analysis reads that as participants preferred placebo, which is a disputed reading of an undisputed number.

Question 13

Who was excluded from the trials?

Accepted Answer

This is the most useful section for anyone outside the trial population, and everyone enrolled was a premenopausal woman with one diagnosis. Most participants were white (85.6%), from U.S. sites (96.6%), and had a mean age of 39 years. That rules out men, postmenopausal women, and anyone whose low desire has another cause, since the diagnosis was an entry condition. Breastfeeding is an open gap. A lactation reference states that no information is available on the clinical use of bremelanotide during breastfeeding. It advises that until more data become available, bremelanotide should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. A Phase 4 study measuring the concentration of bremelanotide in breast milk, in ten women, has completed without a published result. People at cardiovascular risk are the fourth group, and they appear in the label as a caution rather than as a studied population.

Question 14

Is research-grade PT-141 the same as the approved product?

Accepted Answer

No, and this distinction governs everything above. The record on this page belongs to one approved article: a 2019 review describes bremelanotide, sold as Vyleesi, as a self-administered, on-demand subcutaneous therapy, and the trials ran it through an autoinjector at one fixed amount. Three things come with an approval and do not travel. The schedule is one, since the daily and monthly limits were set against that article. The interaction testing is another. The adverse-event percentages are the third, because each was counted in a trial that knew what was in the syringe. A vial labelled PT-141 carries none of those, and no analysis among the research behind this page has measured the contents, concentration or sterility of material sold outside a pharmacy. A 2026 review notes that non-approved peptides lack long-term safety data and systematic validation, while FDA-approved agents demonstrated robust safety profiles from large-scale trials. Here the same molecule sits on both sides of that line.

Question 15

What has not been studied?

Accepted Answer

Three newer uses are under study, and none has a published safety result. One pairs bremelanotide with tirzepatide in 108 people with obesity, and is listed as ACTIVE_NOT_RECRUITING. A second, in Diabetic Kidney Disease, ran in sixteen people and has completed. A third asked a narrower question, and it was a Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran, in 228 people. Zofran is an anti-sickness medicine, and a 228-person trial built around nausea says something about the size of that problem. A 2026 review of peptides in skin and metabolic medicine holds that further studies are needed before most new peptides can be used safely in humans. For bremelanotide the approved use is that exception, and nothing outside it is.

PT-141 side effects and safety data